You are here:

Forthcoming Submission: atezolizumab (Tencentriq)

Indication: As monotherapy, indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) after prior platinum - containing chemotherapy or who are considered cisplatin.

Drug Details

Drug Name: atezolizumab (Tencentriq)
Drug Manufacturer: Roche
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 6/02/2018
Advice Due: 12/03/2018